Gut Bacteria Predict Lung Cancer Treatment Success and Side Effects

The gut microbiome may hold the key to predicting which lung cancer patients will respond best to immunotherapy, according to groundbreaking research from a major Japanese clinical trial. This finding could revolutionize how doctors select treatments for advanced non-small cell lung cancer.

Researchers analyzed gut bacteria samples from 270 treatment-naive patients with advanced lung cancer participating in the JCOG2007 trial, which compared two immunotherapy combinations: pembrolizumab plus chemotherapy versus nivolumab/ipilimumab plus chemotherapy.

Patients with higher levels of beneficial bacteria—particularly Fusicatenibacter, Butyricicoccus, and Blautia—survived significantly longer than those without these microbes. The effect was most pronounced with nivolumab/ipilimumab treatment, where patients with abundant Fusicatenibacter and Butyricicoccus had roughly half the mortality risk. Conversely, patients with higher levels of Prevotellaceae NK3B31 bacteria faced more than double the death risk on this regimen.

The microbiome also predicted treatment toxicity. Patients with lower bacterial diversity and certain harmful taxa experienced more severe side effects, while those with beneficial bacteria had fewer serious complications.

These findings suggest gut microbiome profiling could become a standard tool for personalizing lung cancer treatment, helping oncologists choose between different immunotherapy regimens based on each patient's bacterial signature. This represents a major step toward precision medicine in cancer care, potentially improving both survival outcomes and quality of life.